$IRON

Yu Jonathan Yen-Wen sold $705K of IRON

Yu Jonathan Yen-Wen (Chief Operating Officer) sold 9,700 shares of Disc Medicine, Inc. (IRON) at $72.66 ($0.70M total) on 2026-06-22 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Yu Jonathan Yen-Wen
Published Jun 25, 2026, 12:34 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jun 25, 2026, 12:35 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$IRON
Neutral
high confidence
Mentioned
$IRON
Relevance
4/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$IRONNeutralLow
01

Why it matters

The disclosed sale size (~$705K) is moderate and, because it is 10b5-1 pre-arranged, is typically treated as lower-signal for near-term valuation changes.

02

Market read

Traders may note the insider sale for sentiment monitoring, but the 10b5-1 structure limits actionable inference.

03

What to watch

The article provides no context on total insider holdings beyond the post-sale figure, and 10b5-1 plans are designed to be non-informational.

Relevance 4/10Novelty 3/10Timing: after-hours / latest SEC Form 4 disclosure (filed 2026-06-24)

Background

This is an SEC Form 4 insider transaction for Disc Medicine, Inc. (IRON) by its COO, reported as an open-market sale under a pre-arranged 10b5-1 plan.

Company-level read

Ticker impact

$IRONNeutralHigh confidence
Context

Disc Medicine COO Yu Jonathan Yen-Wen sold 9,700 shares at $72.6593 in an SEC Form 4 filed June 24, 2026.

Expected impact

Limited immediate impact; any effect is likely short-lived and outweighed by broader market factors.

Evidence & confidence

The filing is a Form 4 insider transaction with explicit 10b5-1 pre-arrangement, reducing interpretive signal versus discretionary selling.

Market effects

No clear sector read-through from a single 10b5-1 insider sale.

None indicated.

None indicated.

Counterpoint

Even with 10b5-1, repeated insider sales can coincide with liquidity needs or portfolio rebalancing rather than bearish fundamentals.

Key entities

  • Disc Medicine, Inc.

    Subject of the Form 4 insider transaction; ticker IRON.

  • Yu Jonathan Yen-Wen

    Chief Operating Officer who sold 9,700 shares at $72.6593 under a 10b5-1 plan.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$JNJMedAI 8/10

Weekly Buzz: JNJ Wins FDA Nod; AXGN, HCWB Strike Deals; ROIV, AZN, GPCR Lead Clinical Trials

Johnson & Johnson (JNJ) received CE Marking for ACUVUE OASYS MAX 2-Week contact lenses. GSK (GSK) expanded Shingrix approval in Japan. Axogen (AXGN) to acquire BioCircuit for $200M. Femasys (FEMY) partnered with CapexMD for fertility financing. EpilepsyGTx collaborated with Viralgen (BAYN.DE) for gene therapy. HCW Biologics (HCWB) partnered with Akron Biotech. Bluejay Diagnostics (BJDX) teamed with Lovell for federal market access. Transgene (TNG.PA) expanded partnership with ProBioGen. Oncolyti

$NEEMed

SMALL-CAP MOVERS: Britain's bargain basement and the overseas buyers who can't believe their luck

The article reports AIM takeover activity: Gooch & Housego PLC is being acquired in a £346m deal, and Ramsdens Holdings PLC is set to be bought for £230m. It also notes NextEnergy Solar rose 10% after putting itself up for sale, and highlights large AIM share moves for Ironveld, Itaconix, Jersey Oil and Gas, Safestay, Galileo Resources, and Iofina. Iofina reported 393.3 tonnes H1 2026 and raised guidance to 460-485 tonnes.

$IRONMed

Ironveld shares jump 32% at 0.025p as processing plant hits sustained production

Ironveld PLC (AIM:IRON) shares rose 32% to 0.025p after the company said its dense media separation plant reached sustained production. It now runs 16 hours daily on double shift, processing 2.5-3.5 tonnes per hour and producing 1.4 tonnes/hour in-spec magnetite plus about 1 tonne/hour maghemite. Three clients secured, with a 5,000 tonnes/month buyer sampling; expansion options and Mintek study ongoing.

$IRONMed

Disc Medicine Presents Positive Clinical Updates at the 2026 European Hematology Association (EHA) Annual Meeting

Disc Medicine (NASDAQ:IRON) reported updated clinical data at the 2026 EHA meeting in Stockholm. In RALLY-MF, DISC-0974 showed durable overall anemia responses in myelofibrosis across subgroups, including 55% major hemoglobin response in non-transfusion dependent patients and transfusion independence in 64% (TD Low) and 50% (TD High). In HELIOS, bitopertin sustained PPIX reductions and improved light tolerance with favorable longer-term safety. A corporate call is set for June 15.

$IRONLow

Rosen Law Firm Encourages Disc Medicine, Inc. Investors to Inquire About Securities Class Action Investigation - IRON

Rosen Law Firm said it is investigating potential securities claims for Disc Medicine, Inc. (NASDAQ: IRON) shareholders, alleging materially misleading business information. The firm cited an FDA Complete Response Letter on Feb. 13, 2026 for Disc Medicine’s bitopertin NDA, citing uncertainties needing more evidence; IRON shares fell 22% that day.